PMN : TSX | ARFXF : OTCQB
Developing Treatments for Neurodegenerative Diseases
ProMIS is focused on using their unique technology to develop highly selective antibody treatments for neurodegerative diseases - Alzheimer's, ALS and Parkinson's disease.
ProMIS will continue to demonstrate potential for their drug as best in its class Alzheimer's therapy and initiate clinical trials in 2019.
Their lead drug candidate for Alzheimer's, selectively blocks what the expert community now identifies as the root cause of Alzheimer’s disease.
Massive Unmet Medical Need
Broad Product Portfolio in Neurodegenerative Diseases
Experienced, complementary management team with outstanding scientific and business advisory boards.
No therapies available today to stop the progression of Alzheimer’s disease (AD)
Total US AD healthcare costs > $500BB, expected to triple over next 10-15 years
Discovery platform allows identification of therapeutic targets on various toxic proteins responsible for diseases, including Alzheimer’s disease, Parkinson’s disease, ALS, and other dementias
Copyright © 2018. All rights reserved.